Potentiating oncolytic viruses by targeted drug intervention

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 4, 2010, Pages 394-402

  Mahoney, Douglas J ^a,b   Stojdl, Dave F ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DICHLOROACETIC ACID; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; OMACETAXINE MEPESUCCINATE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC PARVOVIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC SINDBIS VIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; OXALIPLATIN; PACLITAXEL; RAPAMYCIN; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; FUNCTIONAL GENOMICS; GENETIC SCREENING; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; RNA INTERFERENCE; TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG SCREENING; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 77955400126     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Gapstur SM, Thun MJ: Progress in the war on cancer. JAMA (2010) 303(11):1084-1085.
2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM: The global burden of cancer: Priorities for prevention. Carcinogenesis (2010) 31(1):100-110.
3. Belani CP: Non-small-cell lung cancer have we reached a "chemotherapy efficacy plateau"? Clin Lung Cancer (2000) 2(1):10.
4. Murdoch D, Sager J: Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol (2008) 20(1): 104-111.
5. Cheong K, Spicer J, Chowdhury S, Harper P. Combination therapy versus single agent chemotherapy in non-small cell lung cancer. Expert Opin Pharmacother (2005) 6(10):1693-1700.
6. Dougan M, Dranoff G: Immune therapy for cancer. Annu Rev Immunol (2009) 27:83-117.
7. Sinkovics JG, Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) (2008) 56(Suppl 1):3s-59s.
8. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett (2007) 254(2):178-216.
9. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science (1998) 282(5392):1332-1334.
10. Gnant MF, Noll LA, Irvine KR, Puhlmann M, Terrill RE, Alexander HR Jr, Bartlett DL. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst (1999) 91(20):1744-1750. (Pubitemid 29518770)
11. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 6(7):821-825.
12. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 4(4):263-275.
13. Liu T-C, Galanis E, Kirn D: Clinical trial results with oncolytic virotherapy. A century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 4(2):101-117.
14. Alvarez-Breckenridge C, Kaur B, Chiocca EA: Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 109(7):3125-3140.
15. Nguyen TL, Tumilasci VF, Singhroy D, Arguello M, Hiscott J. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol (2009) 11(6): 889-897.
16. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design. Combination therapy with oncolytic viruses. Mol Ther (2010) 18(2):251-263.
17. Schache P, Grlevik E, Strver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Khnel F, Kubicka S: VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther (2009) 16(7):849-861.
18. Warr MR, Shore GC: Unique biology of Mcl-1: Therapeutic opportunities in cancer. Curr Mol Med (2008) 8(2):138-147.
19. McNally LR, Rosenthal EL, Zhang W, Buchsbaum DJ: Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther (2009) 16(3):246-255.
20. Israyelyan A, Shannon EJ, Baghian A, Kearney MT, Kousoulas KG. Thalidomide suppressed the growth of 4T1 cells into solid tumors in BALB/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother Pharmacol (2009) 64(6):1201-1210.
21. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/Herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 59(16):3861-3865.
22. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med (2006) 47(7):1136-1143.
23. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR, Bartlett DL: Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vacciniamediated tumor regression. Gene Ther (2000) 7(14):1217-1223.
24. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic Herpes simplex virus for enhanced local tumor control. Cancer Res (2006) 66(9):4835-4842.
25. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, et al.: Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA (2008) 105(39):14981-14986.
26. Tumilasci VF, Olire S, Nguyn TL-A, Shamy A, Bell J, Hiscott J: Targeting the apoptotic pathway with Bcl-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol (2008) 82(17):8487-8499.
27. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC, Thomas G, et al.: Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA (2010) 107(4):1576-1581.
28. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA: Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin. Cancer Res (2010) 70(2):598-608.
29. Chang CL, Ma B, Pang X, Wu TC, Hung CF: Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther (2009) 17(8):1365-1372.
30. Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D: Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther 17(4):244-255.
31. Gros A, Puig C, Guedan S, Rojas JJ, Alemany R, Cascallo M. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther (2010) 18(5):903-911.
32. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K: The role of angiogenesis in solid tumours: An overview. Eur J Intern Med (2009) 20(7):663-671.
33. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, et al.: Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 15(9):1686-1693.
34. Michieli P: Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe? Cell Cycle (2009) 8(20):3291-3296.
35. Moffat J, Sabatini DM: Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol (2006) 7(3):177-187.
36. Butland G, Babu M, Díaz-Mejía JJ, Bohdana F, Phanse S, Gold B, Yang W, Li J, Gagarinova AG, Pogoutse O, Mori H, et al.: eSGA: E. coli synthetic genetic array analysis. Nat Methods (2008) 5(9):789-795.
37. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Véronneau S, Dow S, Lucau-Danila A, Anderson K, André B, Arkin AP, et al.: Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 418(6896):387-391.
38. Ramet M, Manfruelli P, Pearson A, Mathey-Prevot B, Ezekowitz RA: Functional genomic analysis of phagocytosis and identification of a Drosophila receptor for E. coli. Nature (2002) 416(6881):644-648.
39. Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J: Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature (2000) 408(6810):325-330.
40. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669): 806-811. (Pubitemid 28099681)
41. Friedman A, Perrimon N: A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature (2006) 444(7116):230-234.
42. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, et al.: Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA (2008) 105(51): 20380-20385.
43. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, et al. Systematic RNA interference reveals that oncogenic KRASdriven cancers require TBK1. Nature (2009) 462(7269):108-112.
44. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy. Oncogene and non-oncogene addiction. Cell (2009) 136(5): 823-837.
45. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K,, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 137(5):821-834.
46. Duan Z, Weinstein EJ, Ji D, Ames RY, Choy E, Mankin H, Hornicek FJ: Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther (2008) 7(8):2377-2385.
47. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 26(24):9377-9386.
48. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, et al.: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 446(7137): 815-819.
49. Canaani D: Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br J Cancer (2009) 100(8):1213-1218.
50. Gaither LA: Chemogenomics approaches to novel target discovery. Expert Rev Proteomics (2007) 4(3):411-419.
51. Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, et al.: A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 18(6):1123-1129.
52. Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, et al.: Identification of the Ent1 antagonists dipyridamole and dilazep as amplifiers of oncolytic Herpes simplex virus-1 replication. Cancer Res (2010) 70(10):3890-3895.
53. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 252(5007):854-856.
54. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 16(4):324-335.
55. Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet (2009) 41(10):1133-1137.
56. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, et al.: An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 135(5):852-864.
57. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, et al.: Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther (2007) 15(5):1016-1023. (Pubitemid 46621661)
58. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH: Phase I study of replication-competent adenovirus-mediated doublesuicide gene therapy in combination with conventionaldose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res (2003) 63(21):7497-7506.
59. Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, Jooss K: Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer. Cancer Gene Ther (2009) 16(5):383-392.
60. Kondo N, Tsukuda M, Kimura M, Fujita K, Sakakibara A, Takahashi H, Ishiguro Y, Toth G, Matsuda H: Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol Rep (2010) 23(2):355-363.
61. Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, Li N, Wang YG: Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin (2009) 30(4):467-477.
62. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R: Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 15(19):6158-6166.
63. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 8:47.
64. Ziauddin MF, Guo ZS, OMalley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther (2010) 17(4):550-559.
65. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer (2009) 100(7):1154-1164.
66. Meng HT, Li L, Liu H, Wang Y, Li GC, Qian WB: Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines. Acta Pharmacol Sin (2009) 30(11):1529-1536.
67. Halldén G: Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. J BUON (2009) 14(Suppl 1):S61-S67.
68. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res (2009) 15(5):1730-1740.
69. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T: Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther (2009) 8(4):980-987.
70. Nelson AR, Davydova J, Curiel DT, Yamamoto M: Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci (2009) 100(11):2181-2187.
71. Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z: Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res (2009) 15(2):511-519.
72. Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y: Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem (2010) 340(1-2):31-40.
73. Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen D-T, Diaconu I, Tenhunen M, Liikanen I, Grénman R, Savontaus M, Pesonen S, et al.: Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. Eur J Cancer (2010) 46(3):625-635.
74. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA: Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 15(8):2777-2788.
75. Min HJ, Koh SS, Cho IR, Srisuttee R, Park EH, Jhun BH, Kim YG, Oh S, Kwak JE, Johnston RN, Chung YH: Inhibition of GSK-3β enhances reovirus-induced apoptosis in colon cancer cells. Int J Oncol (2009) 35(3):617-624.